Orgaran® use in intensive care unit patients with heparin-induced thrombocytopenia and acute renal failure
| Autor: | H Magnani, J Wester |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Icu patients business.industry Danaparoid Sodium medicine.medical_treatment Critical Care and Intensive Care Medicine medicine.disease Intensive care unit law.invention law Heparin-induced thrombocytopenia Antithrombotic Emergency medicine Poster Presentation medicine Renal replacement therapy Intensive care medicine business |
| Zdroj: | Critical Care |
| ISSN: | 1466-609X 1364-8535 |
| Popis: | Orgaran® (danaparoid sodium) is a low-molecular-weight, nonheparin glycosaminoglycan antithrombotic that is currently a first-line treatment for heparin-induced thrombocytopenia (HIT). This study reports on the safety of Orgaran® in ICU patients suffering from HIT and acute renal failure requiring continuous renal replacement therapy (haemofiltration). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink